Efficacy and Safety Evaluation of the Traditional Chinese Medicine Treatment 'Fu Pi Shen, Hua Yu Shi' in Delaying the Progression of Chronic Renal Failure

Chongqing Traditional Chinese Medicine Hospital0 个研究点开始时间: 待定最近更新: 2023年12月18日

适应症

试验速览

暂无简介。

•1) Patients diagnosed with chronic kidney disease.
•2) Age = 18 years to = 75 years, both genders.
•3) CKD stage 3-5, with renal function eGFR > 15 to = 60 ml/min/1.73m2 (calculated using the CKD-EPI equation), and no need for blood purification treatment.
•4) Signed informed consent form.

•1) Abnormal liver function (ALT, AST greater than 2.5 times the upper limit of normal).
•2) Patients with a recent history (within three months) of severe cardiovascular diseases such as myocardial infarction, coronary artery bypass grafting, or ischemic heart disease with heart failure (functional class III-IV, NYHA classification).
•3) Patients with a recent history (within three months) of severe cerebrovascular diseases such as stroke, or significant neurological functional impairment after stroke.
•4) Patients with a recent history (within three months) of active gastrointestinal bleeding.
•5) Known severe thrombocytopenia (PLT < 10x109/L) or abnormal coagulation function.
•6) Persistent elevation of blood potassium level > 5.5mmol/L.
•7) History of allergy to the components of the investigational drug.
•8) Pregnant or lactating women.
•9) Patients scheduled for urgent hemodialysis treatment.
•10) Currently using corticosteroids, non-steroidal anti-inflammatory drugs, or immunosuppressive agents.
•11) Other diseases or conditions, as determined by the investigator, that may reduce the likelihood of enrollment or complicate the study, such as mental illness, frequent changes in living and working environment leading to loss to follow-up.

发起方

Chongqing Traditional Chinese Medicine Hospital